Trials / NCT05179460
A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy
Completed Observational Natural history / observational
- Sponsor
- Janssen Research & Development, LLC
- Treatment
- Not listed
- Gene
- Not stated
- Conditions
- Pigmentary Maculopathy, Pigmentary Retinopathy, Interstitial Cystitis
- Ages
- 18 Years to no upper limit
- Enrollment
- 2 participants
- Started
- 2021-10-26
- Main results expected
- 2022-05-20
- Results posted
- Not yet
- Record last updated
- 2025-06-26
What the study is testing
The purpose of this study is to evaluate incidence and prevalence rates of the study endpoints (pigmentary maculopathy [PM]/ pigmentary retinopathy [PR]/Any, PM/PR/ pentosan polysulfate sodium [PPS], and PM/PR/Non-PPS) in relation to PPS exposure, and in participants with interstitial cystitis (IC) but not exposed to PPS; changes in visual acuity (VA) over time; participant treatment journey leading to PPS treatment, and potential risk factors associated with the occurrence of PM/PR/PPS.
Where it runs
United States (1)
- Janssen R&D, LLC, Titusville, New Jersey